JP2007509902A - 薬理学的に活性のある薬剤の送達のためのナノ粒子 - Google Patents

薬理学的に活性のある薬剤の送達のためのナノ粒子 Download PDF

Info

Publication number
JP2007509902A
JP2007509902A JP2006537242A JP2006537242A JP2007509902A JP 2007509902 A JP2007509902 A JP 2007509902A JP 2006537242 A JP2006537242 A JP 2006537242A JP 2006537242 A JP2006537242 A JP 2006537242A JP 2007509902 A JP2007509902 A JP 2007509902A
Authority
JP
Japan
Prior art keywords
nanoparticles
dna
nanoparticle
antigen
tat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006537242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509902A5 (enExample
Inventor
エンソーリ，バルバラ
カプート，アントネラ
ラウス，ミケーレ
トンデッリ，ルイーザ
スパーナッチ，カティア
Original Assignee
イスティチュート スペリオーレ ディ サニータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イスティチュート スペリオーレ ディ サニータ filed Critical イスティチュート スペリオーレ ディ サニータ
Publication of JP2007509902A publication Critical patent/JP2007509902A/ja
Publication of JP2007509902A5 publication Critical patent/JP2007509902A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006537242A 2003-11-03 2004-11-03 薬理学的に活性のある薬剤の送達のためのナノ粒子 Pending JP2007509902A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0325625A GB2407501A (en) 2003-11-03 2003-11-03 Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
PCT/EP2004/012420 WO2005048997A1 (en) 2003-11-03 2004-11-03 Nanoparticles for delivery of a pharmacologically active agent

Publications (2)

Publication Number Publication Date
JP2007509902A true JP2007509902A (ja) 2007-04-19
JP2007509902A5 JP2007509902A5 (enExample) 2007-11-29

Family

ID=29725850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006537242A Pending JP2007509902A (ja) 2003-11-03 2004-11-03 薬理学的に活性のある薬剤の送達のためのナノ粒子

Country Status (5)

Country Link
US (1) US20060280798A1 (enExample)
EP (1) EP1701711A1 (enExample)
JP (1) JP2007509902A (enExample)
GB (1) GB2407501A (enExample)
WO (1) WO2005048997A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010163364A (ja) * 2009-01-13 2010-07-29 Univ Of Tsukuba 四級化アミノ基を有する架橋ポリマー由来のポリマー微粒子と核酸の複合体
CN110808137A (zh) * 2019-11-13 2020-02-18 山东师范大学 一种磁性富集材料、水体细菌检测试剂盒及应用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877250B2 (en) 2005-12-20 2014-11-04 Bridgestone Corporation Hollow nano-particles and method thereof
EP2029119A2 (de) * 2006-06-08 2009-03-04 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste polymernanopartikel für diagnostische und therapeutische anwendungen
US8268948B2 (en) 2006-07-21 2012-09-18 Nektar Therapeutics Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
WO2008085556A2 (en) 2006-09-12 2008-07-17 University Of South Florida Surfactant-free nanoparticles for drug delivery
FR2909094A1 (fr) * 2006-11-28 2008-05-30 Arkema France Memoire optique 3d comprenant des particules multicouches comprenant un monomere photoactif porteur d'un groupement photoisomerisable.
WO2009056344A1 (en) * 2007-11-02 2009-05-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Core-shell macromolecules for specific cell nucleus or/and cell matrix staining
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
WO2010078320A2 (en) * 2008-12-31 2010-07-08 Bridgestone Corporation Core-first nanoparticle formation process, nanoparticle, and composition
US9062144B2 (en) 2009-04-03 2015-06-23 Bridgestone Corporation Hairy polymeric nanoparticles with first and second shell block polymer arms
US11285494B2 (en) 2009-08-25 2022-03-29 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
US10751464B2 (en) 2009-08-25 2020-08-25 Nanoshell Company, Llc Therapeutic retrieval of targets in biological fluids
CN102625710A (zh) 2009-08-25 2012-08-01 艾格尼丝·奥斯塔芬 携氧的抗湍流的高密度亚微米颗粒的合成
US10099227B2 (en) 2009-08-25 2018-10-16 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
IT1397011B1 (it) * 2009-10-14 2012-12-20 Univ Ferrara Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.
US9115222B2 (en) 2009-12-29 2015-08-25 Bridgestone Corporation Well defined, highly crosslinked nanoparticles and method for making same
KR20130100290A (ko) 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법
EP2720682B1 (en) * 2011-06-17 2016-11-23 Evonik Röhm GmbH Coating composition suitable for pharmaceutical or nutraceutical dosage forms
US9428604B1 (en) 2011-12-30 2016-08-30 Bridgestone Corporation Nanoparticle fillers and methods of mixing into elastomers
WO2015026947A1 (en) * 2013-08-21 2015-02-26 The Regents Of The University Of California Composition and methods for culturing cells
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
EP4221685A1 (en) 2020-09-29 2023-08-09 Oxford University Innovation Limited Stroke treatment
WO2022109274A1 (en) * 2020-11-20 2022-05-27 Nouryon Chemicals International B.V. Fluorescent polymers and solutions thereof for scale control in aqueous systems
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US12618094B2 (en) * 2022-01-05 2026-05-05 City University Of Hong Kong Core-shell nanoparticles, methods of producing the same, and uses thereof for detecting extracellular polymeric substances
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
WO2026024279A1 (en) * 2024-07-24 2026-01-29 Kemira Oyj Surfactant compositions derived from waste streams, and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001322347A (ja) * 2000-03-27 2001-11-20 Eastman Kodak Co インクジェット印刷方法
JP2001524531A (ja) * 1997-12-01 2001-12-04 イスティテュート スペリオーレ ディ サニタ 予防的および治療的ワクチン接種用のＨＩＶ−１のＴａｔまたはその誘導体
JP2002534220A (ja) * 1999-01-12 2002-10-15 クアナム メディカル コーポレイション 腔内ステント用の重合体組成物
WO2003045356A1 (en) * 2000-11-20 2003-06-05 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings
WO2003057199A1 (de) * 2002-01-09 2003-07-17 Röhm GmbH & Co. KG Haft- und bindemittel für dermale oder transdermale therapiesysteme

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723218A (en) * 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
DE19614136A1 (de) * 1996-04-10 1997-10-16 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung agglomeratfreier nanoskaliger Eisenoxidteilchen mit hydrolysebeständigem Überzug
DE19746362A1 (de) * 1996-10-23 1998-04-30 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von biologisch aktiven Polymernanopartikel-Nucleinsäure-Konjugaten
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US6974706B1 (en) * 2003-01-16 2005-12-13 University Of Florida Research Foundation, Inc. Application of biosensors for diagnosis and treatment of disease
WO2002000191A2 (de) * 2000-06-29 2002-01-03 Bernina Biosystems Gmbh Bdellosomen
DE10118852A1 (de) * 2001-04-17 2002-10-31 Fricker Gert Bdellosomen
DE10203907A1 (de) * 2002-01-31 2003-08-21 Karlsruhe Forschzent Fluoreszierende Nanoteilchen und deren Herstellung

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524531A (ja) * 1997-12-01 2001-12-04 イスティテュート スペリオーレ ディ サニタ 予防的および治療的ワクチン接種用のＨＩＶ−１のＴａｔまたはその誘導体
JP2002534220A (ja) * 1999-01-12 2002-10-15 クアナム メディカル コーポレイション 腔内ステント用の重合体組成物
JP2001322347A (ja) * 2000-03-27 2001-11-20 Eastman Kodak Co インクジェット印刷方法
WO2003045356A1 (en) * 2000-11-20 2003-06-05 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings
JP2005510539A (ja) * 2001-11-23 2005-04-21 ザ プロクター アンド ギャンブル カンパニー 複数のコーティングを有する医薬剤形
WO2003057199A1 (de) * 2002-01-09 2003-07-17 Röhm GmbH & Co. KG Haft- und bindemittel für dermale oder transdermale therapiesysteme
JP2005519054A (ja) * 2002-01-09 2005-06-30 レーム ゲゼルシャフト ミツト ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 皮膚または経皮吸収治療システムのための接着剤および結合剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010163364A (ja) * 2009-01-13 2010-07-29 Univ Of Tsukuba 四級化アミノ基を有する架橋ポリマー由来のポリマー微粒子と核酸の複合体
CN110808137A (zh) * 2019-11-13 2020-02-18 山东师范大学 一种磁性富集材料、水体细菌检测试剂盒及应用

Also Published As

Publication number Publication date
WO2005048997A1 (en) 2005-06-02
US20060280798A1 (en) 2006-12-14
GB2407501A (en) 2005-05-04
EP1701711A1 (en) 2006-09-20
GB0325625D0 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
US20060280798A1 (en) Nanoparticles for delivery of a pharmacologically active agent
Xiang et al. Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles
ES2344303T3 (es) Particulas que comprenden un nucleo de nanoparticulas de fosfato calcico, una biomolecula y un acido biliar, los metodos de produccion y el uso terapeutico de las mismas.
US9950051B2 (en) Formulations
EP2464341B1 (en) Immunomodulatory compositions comprising a polymer matrix and an oil phase
Courant et al. Tailoring nanostructured lipid carriers for the delivery of protein antigens: Physicochemical properties versus immunogenicity studies
Rose et al. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522
ES2248914T3 (es) Agentes bioactivos encapsulados de liberacion rapida que permiten inducir o potenciar una respuesta inmunitaria y metodos para utilizar los mismos.
Castaldello et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination
Chen et al. Pollen-mimetic metal–organic frameworks with tunable spike-like nanostructures that promote cell interactions to improve antigen-specific humoral immunity
JP2003528024A (ja) 製剤化された核酸分子の無針注入
CN104338126B (zh) 一种具有治疗或预防hpv病毒的疫苗组合物及其应用
Avila et al. Gene delivery and immunomodulatory effects of plasmid DNA associated with Branched Amphiphilic Peptide Capsules
US20210100880A1 (en) System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
JP2012515201A (ja) 改変された生分解速度論を有する多孔性構造
Voltan et al. Preparation and characterization of innovative protein-coated poly (methylmethacrylate) core-shell nanoparticles for vaccine purposes
Lee et al. Virus-mimetic polymer nanoparticles displaying hemagglutinin as an adjuvant-free influenza vaccine
Zhao et al. Self-adjuvanting polymeric nanovaccines enhance IFN production and cytotoxic T cell response
US20070275071A1 (en) Use of Microparticles for Antigen Delivery
Bos et al. Cationic polymers that enhance the performance of HbsAg DNA in vivo
Panda Nanotechnology in vaccine development
Singh et al. Applications of nanotechnology in vaccine delivery
White et al. Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants
Dong et al. Nano-delivery vehicles/adjuvants for DNA vaccination against HIV
WO2021081043A1 (en) Mucus penetrating particle compositions and methods of use thereof enhancing immune response

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110701